- Raised grant, Jun 2024
- Raised Seed round led by Dan Launchpad, Jan 2024
About
Saforax (Safe-for-Thorax) is an innovative medical device designed to transform chest drainage procedures, making them accessible at the point of injury, to lower-skilled practitioners, including those in high-stress environments like battlefields. With chest injuries being the second leading cause of preventable death in combat, Saforax addresses a critical need for rapid, safe intervention. The device simplifies chest tube insertion with intuitive, user-friendly features, enabling EMT-Basics, combat medics, and other lower-trained personnel to perform chest decompression safely and effectively, even with minimal training. Preliminary results indicate that Saforax is safe, even in cases of misdiagnosis, and allows for alternative placement outside traditional anatomical "safe zones." Its minimally invasive design promotes faster recovery, reduces pain, and lowers the risk of infections, potentially decreasing overall healthcare costs. With its standardized, reliable, and cost-effective approach to chest drainage, Saforax aims to set a new benchmark for trauma care and chest tube insertion in both military and civilian settings.
Funding history · 2 rounds · $10K total
Q&A
- What is Saforax's primary focus?
- Saforax (Safe-for-Thorax) is developing an innovative medical device to revolutionize chest drainage procedures, making them accessible at the point of injury for lower-skilled practitioners.
- When was Saforax founded?
- Saforax was founded in January 2024.
- What is the primary sector for Saforax?
- Saforax operates in the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Life Support.
- What kind of funding has Saforax received?
- Saforax received a Grant in June 2024.
- Who is the CTO of Saforax?
- Yonatan Hayoun is the CTO and a founder of Saforax.
- What is the estimated market growth for chest drainage devices?
- The global chest drainage devices market is projected to grow from $1.02 billion in 2024 to $1.74 billion by 2034.
- What problem does Saforax aim to solve in trauma care?
- Saforax aims to address the critical need for rapid, safe intervention for chest injuries, which are the second leading cause of preventable death in combat, by simplifying chest tube insertion for lower-trained personnel.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2024-1 |
|---|---|
| Employees (exact) | 2 |
Radar intelligence
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 517048906 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2024-09-30 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Active charges / liens | 0 |
| Registry events | 2 — shares_capital (1), violation (1) |
| Registered address | הרב ברלין 20 ירושלים |
Recent registry events
| Date | Event |
|---|---|
| 2026-01-08 | העברת מניות |
| 2026-06-04 | עדכון הפרה |